Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADVR: BULLS AND BEARS! -- Ignore unavailable to you. Want to Upgrade?

To: KAKALAK who wrote (8724)	2/16/2000 2:47:00 PM
From: Bill Evans	Respond to of 8902

Will the volume hit 30 million today? TIP TOP.

To: KAKALAK who wrote (8724)	2/16/2000 3:09:00 PM
From: Steve D.	Respond to of 8902

KaKaLaK: Thank you for the post. However could you explain to me what/if ADVR has to do with HGSI. Are they working with each other? Is this just an assumption? and information would be helpful. Thanks again. Steve

To: KAKALAK who wrote (8724)	2/16/2000 3:13:00 PM
From: Walter Morton	Read Replies (1) \| Respond to of 8902

...the FDA classified Reticulose as a "new drug" requiring FDA approval prior to any sale in the United States. Reticulose has not been approved for sale or use by the FDA or any foreign government body, and thus we have not as yet commenced any commercial operations. We are dependent on registration and/orapproval by applicable regulatory authorities of Reticulose in order to commence commercial operations. Our operations over the last five years have been limited principally to engaging in research, IN VITRO testing and analysis of Reticulose in theUnited States, and engaging others to perform testing and analysis of Reticulose on human patients overseas. The FDA has not approved human clinical trials for Reticulose in the United States. ADVANCED VIRAL RESEARCH CORP filed this S-1 on 01/12/2000